Information:
Fel:
ID
26211
Beskrivning
A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00669591
Länk
https://clinicaltrials.gov/show/NCT00669591
Nyckelord
Versioner (1)
- 2017-10-11 2017-10-11 -
Rättsinnehavare
See clinicaltrials.gov
Uppladdad den
11 oktober 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Breast Cancer NCT00669591
Eligibility Breast Cancer NCT00669591
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT00669591
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Adult | Gender | Age | Life Expectancy
Item
adult females over age 18 with life expectancy of at least 3 months
boolean
C0001675 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
C0001779 (UMLS CUI [3])
C0023671 (UMLS CUI [4])
C0079399 (UMLS CUI [2])
C0001779 (UMLS CUI [3])
C0023671 (UMLS CUI [4])
Locally advanced breast cancer | Secondary malignant neoplasm of female breast
Item
histologically or cytologically confirmed locally advanced or metastatic breast cancer
boolean
C3495949 (UMLS CUI [1])
C0346993 (UMLS CUI [2])
C0346993 (UMLS CUI [2])
Prior Chemotherapy Quantity | Docetaxel Absent
Item
one and only one prior chemotherapy regimen (no prior docetaxel)
boolean
C1514457 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0246415 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C1265611 (UMLS CUI [1,2])
C0246415 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Measurable Disease Longest Diameter | Measurable Disease Longest Diameter Spiral CT | Target Lesion Quantity
Item
measurable disease (at least one target lesion)at least 2 cm in longest diameter (1 cm by spiral ct)
boolean
C1513041 (UMLS CUI [1,1])
C0552406 (UMLS CUI [1,2])
C1513041 (UMLS CUI [2,1])
C0552406 (UMLS CUI [2,2])
C0860888 (UMLS CUI [2,3])
C2986546 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0552406 (UMLS CUI [1,2])
C1513041 (UMLS CUI [2,1])
C0552406 (UMLS CUI [2,2])
C0860888 (UMLS CUI [2,3])
C2986546 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
Hematologic function | Renal function | Liver function
Item
adequate hematologic, renal, and hepatic function;
boolean
C0221130 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
Bleeding tendency | Blood Coagulation Disorders
Item
known history of bleeding diathesis or coagulopathy
boolean
C1458140 (UMLS CUI [1])
C0005779 (UMLS CUI [2])
C0005779 (UMLS CUI [2])
Hemorrhage
Item
any current evidence of clinically significant bleeding
boolean
C0019080 (UMLS CUI [1])
Thromboembolism
Item
any history of thromboembolic events
boolean
C0040038 (UMLS CUI [1])
Hormone Therapy
Item
concurrent hormone therapy
boolean
C0279025 (UMLS CUI [1])
Immunotherapy Measurable Disease | Therapeutic radiology procedure Measurable Disease | Exception Recurrent disease Post Therapeutic radiology procedure
Item
prior immunotherapy or radiotherapy to an area of measurable disease unless disease has recurred after radiotherapy
boolean
C0021083 (UMLS CUI [1,1])
C1513041 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2,1])
C1513041 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0277556 (UMLS CUI [3,2])
C0687676 (UMLS CUI [3,3])
C1522449 (UMLS CUI [3,4])
C1513041 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2,1])
C1513041 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0277556 (UMLS CUI [3,2])
C0687676 (UMLS CUI [3,3])
C1522449 (UMLS CUI [3,4])